Washington Insider Articles

Republican's bill to reform FDA, save jobs

February 01, 2012

Sen. Dan Coats (R-IN) has introduced a bill to clarify and reform FDA's mission in order to keep jobs from going overseas.
 

New drug sponsors cause FDA chaos

February 01, 2012

"Emerging sponsors" or companies that have never had an approved application to market a drug are wreaking havoc on review activities at FDA's drugs center, says Office of New Drugs director John Jenkins.
 

As I See it: Conflict-of-interest rules

Paul D. Thacker January 01, 2012

Watching pharma executives, sometimes you have to wonder, "Will these guys ever learn?" Case in point, industry's assault on the FDA's conflict-of-interest rules.
 

New approval paths are needed, says Woodcock

January 01, 2012

FDA director of drugs Janet Woodcock says she is so optimistic that biomedical science and the war on cancer will produce "startlingly better" therapies that the research community should develop new approval paths.
 

Extend brand exclusivity: researchers

January 01, 2012

Researchers are urging Congress to extend the exclusivity period for branded drugs by seven years and remove the initial 180-day marketing exclusivity granted to first-to-file generics.
 

As I See It: Risk management

December 01, 2011

Risk management means more than REMS strategies and tactics, or validated methodologies and therapeutic regis­tries. What it's really about is assuming the mantle of responsibility.
 

Senators try to clear path for new antibiotics

December 01, 2011

Sens. Richard Blumenthal and Bob Corker introduce the Generating Antibiotic Initiatives Now (GAIN) Act to spur antibiotic development to fight the spread of antibiotic-resistant bacteria.
 

Woodcock: More tech, less scrutiny

December 01, 2011

FDA drugs director Janet Woodcock says the next 25 years could bring advances with the potential to make drug development more reliable—and decrease regulatory oversight
 

As I See It: Anti-corporation protests

November 01, 2011

Anti-corporation protests on Wall Street and beyond send a message that pharmaceutical marketers and regulators alike should ponder.
 

FDA, NIH working to speed new antibiotics

November 01, 2011

Working with the private-public Biomarkers Consortium at the Foundation for the National Institutes of Health, FDA is looking at options to ease the development path for antibiotics.
 
« Previous
Next »

Video Exclusive

Web Exclusives

Five industry experts advise specialty pharma company on digital strategy

April 20, 2012

Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
 

MM&M Awards 2011 HIghlights

The Best MM&M Awards Ever!

MAHF Ceremony 2012

Photos from the Medical Advertising Hall of Fame Awards ceremony
 
Popular Topics
Acquisition Adherence Advertising App Celebrity Clinical Trial Co-Marketing Diabetes Diagnostics Digital Direct To Consumer (DTC) Disease Awareness Downsize DTC Education & Awareness FDA Food FTC Government Guidance Health Plans HMOs Hospitals Marketing Research Sales Force